Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Alpha Psychiatry

Depression’s Shadow in First-Onset Schizophrenia: Mapping the Burden and Clinical Significance in Drug-Naïve Patients

  • Lin Zhang1
  • Jie Zhang1
  • Lu Wen1
  • Xinming Pan1
  • Hongjun Mao1
  • Xiao-E Lang2
  • Junjun Liu3
  • Xiangyang Zhang4
4 affiliations
  1. 1Department of Psychiatry, The Second People’s Hospital of Jiangning District, 211103 Nanjing, Jiangsu, China
  2. 2Department of Psychiatry, First Hospital of Shanxi Medical University, 030001 Taiyuan, Shanxi, China
  3. 3Department of Psychiatry, Nanjing Meishan Hospital, 210039 Nanjing, Jiangsu, China
  4. 4CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 100000 Beijing, China
Read full textPDFDOICite

Abstract

Background:: Severe depressive symptoms (SDS) are common in patients with schizophrenia (SZ) and are associated with poor prognosis, reduced quality of life, and an increased risk of suicide. However, the prevalence of SDS and its key associated factors in first-onset drug-naïve patients with SZ remain unclear.

Methods:: This cross-sectional study enrolled 320 inpatients diagnosed with SZ according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), including 164 males and 156 females, aged 18 to 60 years, with a mean disease duration of 2.18 years. The severity of psychotic symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS), anxiety symptoms were evaluated using the Hamilton Anxiety Rating Scale (HAMA), and SDS were assessed using the Hamilton Depression Rating Scale (HAMD). A history of suicide attempts was obtained through standardized interviews. The Kolmogorov-Smirnov test was used to assess the normality of continuous variables. Bonferroni correction was applied to all between-group comparisons of continuous and categorical variables. Univariate analyses and multivariable logistic regression were performed to identify factors independently associated with SDS. A sensitivity analysis excluding patients with a disease duration greater than 12 months was conducted to assess the robustness of the findings.

Results:: Among the 320 patients with SZ, 159 (49.7%) met the criteria for comorbid SDS. After adjustment for age, sex, disease duration, and marital status, multivariable logistic regression analysis demonstrated that higher PANSS scores (OR = 1.045, 95% CI: 1.024 to 1.067, p < 0.001), higher HAMA scores (OR = 1.284, 95% CI: 1.198 to 1.376, p < 0.001), and a history of suicide attempts (OR = 1.513, 95% CI: 1.222 to 1.875, p < 0.001) were independently associated with comorbid SDS. Excluding patients with a disease duration greater than 12 months (n = 138) did not materially alter the results. Furthermore, a combined model incorporating these three variables demonstrated excellent discriminatory performance, with an area under the receiver operating characteristic curve (AUC) of 0.937 (95% CI: 0.904 to 0.958, p < 0.001).

Conclusions:: Severe depressive symptoms are highly prevalent among first-onset, drug-naïve patients with schizophrenia and are independently associated with more severe psychotic symptoms, greater anxiety severity, and a history of suicide attempts. These findings provide important evidence to support early screening and targeted interventions for this vulnerable patient population.

Related

  1. Clinical significance of ultra-low-amplitude electrograms during lattice-tip atrial mapping.
    Akinobu Mizutani, Masato Okada, Mebae Mizutani +2
    HeartRhythm case reportsPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMC
  2. Impact of constipation on patients with schizophrenia and depression: an internet-based survey (CONSIDER survey).
    Hikaru Hori, Hiroyoshi Takeuchi, Shinji Yoneda +5
    Frontiers in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMCCrossref
  3. Mapping Psychosocial Disability in Schizophrenia: Network Analysis of a Relatives-Rated Clinical Scale
    S. F. Frileux, N. Vidal, E. Brunet +1
    European PsychiatryPeer-reviewedCC BYFull text1 citedPsychiatry & mental healthHAL
  4. Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis
    Sehreen Tory, Md. Mojahidur Hasan, Yusuf Kemal Arslan +2
    Asian Pacific Journal of Cancer Prevention : APJCPPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  5. Clinical Significance of Klotho, Fibroblast Growth Factor 23, and Their Ratio for Acute Kidney Injury in Sepsis Patients
    Sumian Dou, Yuchao Shen, Botao Zhao +7
    Medical Principles and PracticePeer-reviewedCC BY 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{zhang2026depressions,
  title = {{Depression’s Shadow in First-Onset Schizophrenia: Mapping the Burden and Clinical Significance in Drug-Naïve Patients}},
  author = {Lin Zhang and Jie Zhang and Lu Wen and Xinming Pan and Hongjun Mao and Xiao-E Lang and Junjun Liu and Xiangyang Zhang},
  journal = {Alpha Psychiatry},
  year = {2026},
  month = oct,
  doi = {10.31083/ap53584},
  url = {https://doi.org/10.31083/ap53584},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Depression’s Shadow in First-Onset Schizophrenia: Mapping the Burden and Clinical Significance in Drug-Naïve Patients
AU  - Lin Zhang
AU  - Jie Zhang
AU  - Lu Wen
AU  - Xinming Pan
AU  - Hongjun Mao
AU  - Xiao-E Lang
AU  - Junjun Liu
AU  - Xiangyang Zhang
PY  - 2026
DA  - 2026/10/26
JO  - Alpha Psychiatry
DO  - 10.31083/ap53584
UR  - https://doi.org/10.31083/ap53584
AB  - Background:: Severe depressive symptoms (SDS) are common in patients with schizophrenia (SZ) and are associated with poor prognosis, reduced quality of life, and an increased risk of suicide. However, the prevalence of SDS and its key associated factors in first-onset drug-naïve patients with SZ remain unclear.  Methods:: This cross-sectional study enrolled 320 inpatients diagnosed with SZ according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), including 164 males and 156 females, aged 18 to 60 years, with a mean disease duration of 2.18 years. The severity of psychotic symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS), anxiety symptoms were evaluated using the Hamilton Anxiety Rating Scale (HAMA), and SDS were assessed using the Hamilton Depression Rating Scale (HAMD). A history of suicide attempts was obtained through standardized interviews. The Kolmogorov-Smirnov test was used to assess the normality of continuous variables. Bonferroni correction was applied to all between-group comparisons of continuous and categorical variables. Univariate analyses and multivariable logistic regression were performed to identify factors independently associated with SDS. A sensitivity analysis excluding patients with a disease duration greater than 12 months was conducted to assess the robustness of the findings.  Results:: Among the 320 patients with SZ, 159 (49.7%) met the criteria for comorbid SDS. After adjustment for age, sex, disease duration, and marital status, multivariable logistic regression analysis demonstrated that higher PANSS scores (OR = 1.045, 95% CI: 1.024 to 1.067, p < 0.001), higher HAMA scores (OR = 1.284, 95% CI: 1.198 to 1.376, p < 0.001), and a history of suicide attempts (OR = 1.513, 95% CI: 1.222 to 1.875, p < 0.001) were independently associated with comorbid SDS. Excluding patients with a disease duration greater than 12 months (n = 138) did not materially alter the results. Furthermore, a combined model incorporating these three variables demonstrated excellent discriminatory performance, with an area under the receiver operating characteristic curve (AUC) of 0.937 (95% CI: 0.904 to 0.958, p < 0.001).  Conclusions:: Severe depressive symptoms are highly prevalent among first-onset, drug-naïve patients with schizophrenia and are independently associated with more severe psychotic symptoms, greater anxiety severity, and a history of suicide attempts. These findings provide important evidence to support early screening and targeted interventions for this vulnerable patient population.
SN  - 2757-8038
ER  -